# EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

> **NCT06401421** · — · RECRUITING · sponsor: **Exact Sciences Corporation** · enrollment: 1800 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** ctDNA MRD test

## Key facts

- **NCT ID:** NCT06401421
- **Lead sponsor:** Exact Sciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-07
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401421, "EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06401421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*